RGD Reference Report - Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.

Authors: Kassouf, W  Black, PC  Tuziak, T  Bondaruk, J  Lee, S  Brown, GA  Adam, L  Wei, C  Baggerly, K  Bar-Eli, M  McConkey, D  Czerniak, B  Dinney, CP 
Citation: Kassouf W, etal., J Urol. 2008 Jan;179(1):353-8. Epub 2007 Nov 19.
RGD ID: 2289943
Pubmed: PMID:18006009   (View Abstract at PubMed)
PMCID: PMC2680144   (View Article at PubMed Central)
DOI: DOI:10.1016/j.juro.2007.08.087   (Journal Full-text)

PURPOSE: Expression of various members of the ErbB family (epidermal growth factor receptor/ErbB-1, ErbB-2, ErbB-3 and ErbB-4) is associated with disease stage and survival in patients with urothelial carcinoma. We examined the correlation of ErbB family receptor expression with the progression of urothelial carcinoma and survival. MATERIALS AND METHODS: A urothelial carcinoma tissue array was constructed from 248 archival paraffin blocks and quality control studies were ascertained. The tissue microarray was stained for epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4, and analyzed using an automated reader. Patient data included grade, stage, growth pattern, recurrence and survival. RESULTS: Kaplan-Meier estimates of 5-year overall and recurrence-free survival were 58% and 27%, respectively. Patients with high grade, invasive or nonpapillary disease had a worse prognosis than patients with low grade, superficial or papillary disease (p <0.0001). High epidermal growth factor receptor or low ErbB-4 expression was associated with nonpapillary, high grade and invasive tumors as well as with significantly shorter recurrence-free and overall survival (p <0.002, 0.028 and 0.047, respectively). Levels of ErbB-2 and ErbB-3 expression were not associated with overall or recurrence-free survival. CONCLUSIONS: The expression profiles of ErbB-4 and epidermal growth factor receptor are prognostic in urothelial carcinoma. They may help in selecting patients at high risk with bladder cancer for more aggressive therapy.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
urinary bladder cancer disease_progressionIEP 2289943protein:increased expression:urinary bladderRGD 
urinary bladder cancer disease_progressionIEP 2289943protein:decreased expression:urinary bladderRGD 
urinary bladder cancer disease_progressionISOEGFR (Homo sapiens)2289943; 2289943protein:increased expression:urinary bladderRGD 
urinary bladder cancer disease_progressionISOERBB4 (Homo sapiens)2289943; 2289943protein:decreased expression:urinary bladderRGD 

Objects Annotated

Genes (Rattus norvegicus)
Egfr  (epidermal growth factor receptor)
Erbb4  (erb-b2 receptor tyrosine kinase 4)

Genes (Mus musculus)
Egfr  (epidermal growth factor receptor)
Erbb4  (erb-b2 receptor tyrosine kinase 4)

Genes (Homo sapiens)
EGFR  (epidermal growth factor receptor)
ERBB4  (erb-b2 receptor tyrosine kinase 4)


Additional Information